A recent study in Nigeria shows that using Ivermectin-only (IVM) to treat COVID-19 patients is equally as effective as using the HIA triple therapy (Hydroxychloroquine, Ivermectin, and Azithromycin Combination) in all inflammatory, virological, and respiratory endpoints.
This study was set up to compare Ivermectin with Ivermectin plus HCQ+IVM (HIA) treatment.
The study design was a single-blind, randomized, parallel-group study of 2 groups of COVID-19-positive Nigerian patients with 30/31 subjects in each treatment arm.
Thirty patients received ivermectin 200 mcg/kg daily for five days and thirty-one patients received HIA triple therapy. What referred to us HIA triple therapy is the use of Hydroxychloroquine 200mg per day for three days, Ivermectin 200mcg/kg daily for five days, Azithromycin 500mg per day for three days. None of the patients had been vaccinated.
This was a relatively small sample size but it found that both therapies showed significant reductions in inflammation.
Here’s an excerpt from the study:
The ecacy of ivermectin (IVM) against SARS-CoV-2 has been demonstrated in vitro, while several clinical studies suggest that it is ecacious and safe in reducing morbidity and mortality. Hydroxychloroquine HCQ, IVM and azithromycin AZM (HIA therapy) are being used in several low- and middle-income countries (LMICs) where more expensive medications such as remdesivir are out of reach. In this study, we set out to compare the ecacy of IVM monotherapy with HIA combination therapy.
Methods: This was a single-blind, randomized control trial of 2 parallel groups of COVID-19-positive Nigerians. Thirty patients received ivermectin 200 mcg/kg daily for ve days, while 31 patients received HIA triple therapy. The viral cycle threshold (Ct) at pretreatment baseline and days 2, 5 14 and 21 were measured for the E- and N-genes. SPO2 was assessed on a daily basis, while inammatory markers erythrocyte sedimentation rate (ESR), C-reactive protein, and D-dimer and neutrophil/lymphocyte ratios (NLRs) were assessed at baseline and day 7. Clinical status was self-assessed daily on a Likert scale.
Results: The findings suggest that there were no significant differences in the two groups (ivermectin-only IVM and the HIA triple therapy (IVM+) group) with regard to all the variables. Age and sex were similar, as were dose of ivermectin based on weight, need for supplemental oxygen, and need for ventilator. None of the patients had been vaccinated.